Rare Disease Day 2026 | Gene Therapy in Practice

Why It Matters

Accelerating gene‑therapy delivery reshapes rare‑disease care, but demands new hospital logistics and financing models, directly affecting patient outcomes and industry economics.

Key Takeaways

• Gene therapy infrastructure expanding at Johns Hopkins for rare diseases.
• In‑vivo and ex‑vivo approaches require complex coordination and monitoring.
• FDA approved 37 cell/gene therapies; 17 target rare conditions.
• High‑cost, high‑risk treatments demand multi‑year onboarding processes for patients.
• Emerging pipeline predicts multiple new rare‑disease therapies within decade.

Summary

The Rare Disease Day 2026 session titled “Gene Therapy in Practice” highlighted Johns Hopkins’ emerging program to deliver gene‑based treatments for pediatric neuromuscular disorders. Speakers—Dr. Jessica Nance, nurse practitioner Maria Belellios, and pharmacy coordinator Danielle Pennock—outlined the institution’s clinical‑trial legacy, patient‑care pathways, and operational framework.

The panel explained that gene therapies fall into in‑vivo (viral or lipid‑nanoparticle vectors delivered directly) and ex‑vivo (patient‑derived cells modified outside the body). To date the FDA has approved 37 cell and gene products, 17 for rare diseases such as Duchenne muscular dystrophy and spinal muscular atrophy, signaling a shift from broad‑population drugs to monogenic‑targeted solutions.

Historical milestones were cited, from the 1990 proof‑of‑concept in a child with SCID to the tragic Jesse Gelsinger case that prompted stricter safety regulations. The speakers also noted the dramatic price escalation—from $30,000 hepatitis C pills a decade ago to multi‑million‑dollar gene therapies—requiring six‑to‑twenty‑four‑month onboarding, multiple committee reviews, and intensive post‑infusion monitoring.

These developments mean hospitals must build ultra‑coordinated infrastructure, manage unprecedented clinical and financial risk, and prepare for a pipeline that could deliver several new rare‑disease cures in the next five to ten years. For families, the promise of disease‑modifying therapy is tempered by the complexity and cost of delivery.

Original Description

An overview of gene therapy by experts from Johns Hopkins Medicine and Kennedy Krieger Institute. The panel will cover core concepts, current uses (including Duchenne Muscular Dystrophy, Hemophilia B, other genetic disorders, and N-of-1 trials), and the clinical and operational setup needed to deliver these treatments safely. Speakers will outline key barriers (cost, risk, access, and follow-up demands), along with the multidisciplinary roles involved in patient care. The session concludes with a brief look at the gene therapy pipeline and what to expect in the years to come. #rarediseaseday #johnshopkins